VBLT News and Press, Vascular Biogenics Ltd. From 08/13/20

Vascular Biogenics Ltd (VBLT) Q2 2020 Earnings Conference Call August 13, 2020, 08:30 ET Company Participants Michael Wood - LifeSci Advisors Dror Harats - CEO & Director Amos Ron - CFO & Company Secretary Conference Call Participants Kevin DeGeeter - Oppenheimer ...

VBL Therapeutics ( VBLT ) Q2 results : More news on: Vascular Biogenics Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

TEL AVIV, Israel, Aug. 13, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the second quarter ended June 30, 2020, and provided a corporate update. “We have made excellent progress advancing our lead candidate VB-111 during 2020,...

The independent Data Safety Monitoring Committee (DSMC) has completed  second interim analysis for VBL Therapeutics' ( VBLT -5.0% ) ofranergene obadenovec (VB-111) Phase 3 (( OVAL )) trial in platinum-resistant ovarian cancer and recommended that the study continue unmodifi...

EyeGate Pharmaceuticals (NASDAQ: EYEG ) +35%  on development path for conjunctivitis treatment. More news on: EyeGate Pharmaceuticals, Inc., Cellular Biomedicine Group, Inc., Vascular Biogenics Ltd., Stocks on the move, , Read more ...

TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-...

TEL AVIV, Israel, Aug. 03, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio...

Evoke Pharma (NASDAQ: EVOK ) +85%  on FDA approval . More news on: Evoke Pharma, Inc., Theratechnologies Inc., Broadway Financial Corporation, Stocks on the move, , Read more ...

TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ) today presented a late-breaking study showing that its proprietary MOSPD2 bi-specific antibody candidates induced T-cell activation and significantly extended the survival of animals carrying establish...

VBL Therapeutics (NASDAQ: VBLT ) announces new data on its proprietary anti-MOSPD2 antibodies in rheumatoid arthritis (RA). The results are being virtually presented at EULAR. More news on: Vascular Biogenics Ltd., Healthcare stocks news, Stocks on the move, Read more ...